Jacobson Pharma Corporation Limited 2633

FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Name of exempt principal trader:Investec Bank Plc(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereeAdvanced Medical Solutions Group Plc(c) Name of the party to the offer with which exempt principal trader

LONDON, October 02, 2026-- FORM 8.3

Global bond markets have been hit hard, with government borrowing costs in major economies climbing to multi decade highs. Higher yields make dependable cash flows more valuable, which can put steady, needs based sectors like Canadian healthcare in sharper focus. This article walks through three stocks from a curated list of financially solid healthcare businesses, helping you see where some investors are hunting for resilience right now. The three healthcare stocks covered below are just a...

TransMedics Group has seen its share price slide in recent months after a strong multi‑year run, which raises an obvious question for you as an investor. Is the current US$78.64 price still aligned with what the company is earning today, or has sentiment moved ahead of the underlying profit story? Over the past 5 years the stock has gained about 157.4%, which puts real weight on whether the earnings profile can support where the valuation now sits. The business relies on turning highly...

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announced the presentation of key preclinical data for its ASC36_35FDC (ASC36_35 co-formulation) at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting, being held September 28–October 2, 2026, in Milan, Italy (EASD 2026). ASC36_35FDC is a once-monthly to once-quarterly fixed-dose combination injection of ASC36, a peptide amylin receptor agonist, and ASC35, a peptide GLP-1R/GIPR agonist. The study was presented in a sh

Intuitive Surgical (ISRG) grows faster and earns a higher operating margin than any of the five rivals in its health care peer group. It is also the most expensive of the six when price is measured against earnings. It holds that place even after its stock fell 10.3% over the past twelve months. How much more do you pay for a dollar of Intuitive's earnings than for a dollar of a rival's.

On Stocktwits, retail sentiment toward SPY and QQQ remained ‘bullish’ ahead of jobs data.

CVS Health (CVS) stock lost 12.7% in the past month without company news, and peers UnitedHealth, Cigna and Elevance Health fell too. The S&P 500 rose 0.6% over the same month. The shares now trade 22.5% below their 52-week high. How much further could CVS stock fall if the market itself turns down.

Pfizer has been going through a period of transition.

GTN, VICR, EMBJ, WILYY and HEI have been added to the Zacks Rank #1 (Strong Buy) List on October 2, 2026.

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.

Daiichi Sankyo (TSE:4568) is again in focus after IHH Healthcare appealed a Tokyo District Court judgment tied to the Fortis Healthcare acquisition. The appeal was filed to the Tokyo High Court, extending longstanding legal disputes that connect IHH Healthcare, Daiichi Sankyo and Fortis Healthcare. The court action relates to complex cross border issues around control and ownership of Fortis Healthcare that have persisted for years. IHH Healthcare’s Tokyo High Court appeal over the Fortis...

The global AI in healthcare market is projected to grow from USD 36.67 billion in 2026 to USD 194.79 billion by 2031, registering a 39.7% CAGR. Growth is driven by rising hospital adoption, demand for clinical efficiency, personalized care, accurate diagnostics and reduced physician burnout. Cloud-based AI solutions will see the fastest growth, while hospitals and clinics remain the leading end users. Asia Pacific is the fastest-growing region, supported by healthcare digitalization and governme

ProQR Therapeutics (NASDAQ:PRQR) said its first-in-human data for AX-0810 provided dose-dependent evidence that its RNA-editing approach can modulate NTCP, a liver transporter involved in bile acid uptake. The company is developing NTCP programs for cholestatic liver diseases, initially focusing on

Companies In The News Are: ACN, AYI, MCK, PRGS.

Twist Bioscience has seen its assessed fair value move from US$105.30 to US$109.58, a modest reset that feeds into how analysts frame the stock’s price targets. The shift comes as research coverage splits between those pointing to higher peer comparables and AI driven drug discovery potential, and others who argue that recent gains and event driven enthusiasm already price in a lot of good news. In the sections that follow, you will see how these changing targets fit into the broader Twist...

Moderna will replace Warner Bros. Discovery in the Nasdaq-100 before markets open on Oct.9.